KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Gross Margin (2016 - 2026)

Gilead Sciences filings provide 17 years of Gross Margin readings, the most recent being 79.51% for Q4 2025.

  • On a quarterly basis, Gross Margin rose 40.0% to 79.51% in Q4 2025 year-over-year; TTM through Dec 2025 was 78.83%, a 57.0% increase, with the full-year FY2025 number at 78.83%, up 57.0% from a year prior.
  • Gross Margin hit 79.51% in Q4 2025 for Gilead Sciences, roughly flat from 79.8% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 83.52% in Q3 2021 to a low of 63.74% in Q4 2021.
  • Median Gross Margin over the past 5 years was 78.27% (2023), compared with a mean of 77.64%.
  • Biggest five-year swings in Gross Margin: crashed -1743bps in 2021 and later soared 1737bps in 2022.
  • Gilead Sciences' Gross Margin stood at 63.74% in 2021, then rose by 27bps to 81.11% in 2022, then fell by -13bps to 70.62% in 2023, then grew by 12bps to 79.11% in 2024, then rose by 1bps to 79.51% in 2025.
  • The last three reported values for Gross Margin were 79.51% (Q4 2025), 79.8% (Q3 2025), and 78.81% (Q2 2025) per Business Quant data.